Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BNT324 + BNT327 in advanced lung cancer
2024-520238-31-01Phase 2Authorised
- Sponsor
- BioNTech SE
- Start
- Apr 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 11
01
Overview
Phase 2, open-label trial of db-1311 and pumitamig in bronchial carcinoma (8 arms), sponsored by BioNTech SE. Primary endpoints: Dose-limiting toxicities, Treatment-emergent adverse events and 5 more. Planned start Apr 2026; status: authorised.
02
Drugs
db-1311pumitamig
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on 2024-520238-31-01.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-520238-31-01.